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不一致，但是只要在 3’C 或 4’C 上连接一个酰氧基，仍然可以保留白花前胡甲素
























Peucedanum praeruptorum Dunn. (Baihua Qianhu) has been used in traditional 
Chinese medicine for a long time. It is used to treat certain respiratory diseases such 
as cough, asthma, and pulmonary hypertension. It can also be used to cure 
hypertension, heart failure, cancer and so on by modern research. The research on this 
plant is growing fast in recent years. There are already more than 30 coumarin 
chemicals separated from this plant, containing (±)-Praeruptorin A, (±)-Praeruptorin B, 
(+)-Praeruptorin A (+)-Praeruptorin B. 
Above all these chemicals, (±)-Praeruptorin A is mostly cared. For it’s activities 
on the treatment of cardiovascular diseases. In this article, we take (±)-Praeruptorin A 
as a lead compound, and 16 (±)-Praeruptorin A derivatives are synthesized. Some of 
them are tested in the activity of tumor necrosis factor-α expression. 
1, (±)-cis- khellactone is the key intermediate in the synthesis of (±)-Praeruptorin 
A derivatives. And the synthesis of (±)-cis- khellactone contains the synthesis of 
seselin, and the oxidization of seselin. In the usual route of the synthesis of seselin, a 
line type byproduct is produced, which name is xanthyletin, and the purification 
comes difficult for the existence of this chemical. OsO4 is often used in the 
oxidization of seselin to form (±)-cis- Khellactone, but OsO4 is not safe and cheap 
enough.  
This article contains the improvement of the synthesis of (±)-cis- khellactone. 
First seselin is synthesized from 2-methyl-3-butyn-2-ol and 7-hydroxycoumarin by 
alkylation of hydroxy group and Claisen rearrangement. And then oxidative 
ruthenium is used to catalyze and oxidize seselin. Successfully, (±)-cis-khellactone is 
produced. And the total yield is higher, the operation is simplified also. This 
improvement makes the preparation of (±)-Praeruptorin A derivatives in laboratory 
possible. 
2, (±)-cis- khellactone is used as a precursor in the synthesis of (±)-Praeruptorin 
A derivatives. Refering the previous articals, these chemicals are desigened. During 
this periord, the method of syntheis this kind of derivatives is established. 
3, There is an article reported that the absolute configuration is not the 















is to keep an ester bond in the 3’C or 4’C of (±)-cis-khellactone. So the 
trans-3’-hydroxyl -4’-methoxyl-dyhydroseselin is synthesized from epoxidation of 
seselin, then treated with InCl3. Trans-3’-hydroxyl -4’-methoxyl-dyhydroseselin is 
used as a precursor in the synthesis of (±)-Praeruptorin A derivatives. 
Sixteen compounds of (±)-Praeruptorin A derivatives are sythesised. Some of 
them are used to test biological activity. And it is found that Compound 
HDX-PdIa-A-3 is more effective in inhibiting the expression of VCAM-1 than 
(±)-Praeruptorin A. So this compound may has a good activity in the treatment of 
artherosclerosis, and also suggesting a good value of research. 
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第一章 前 言 
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选取 10 只小鼠作为实验， 后取平均值。 终得到的结果如下：维司那定能够













































 (±)-3’-O,4’-O-dicynnamoyl-cis-khellactone  
1.2.4 凯林内酯类化合物的抗 HIV 研究 
艾滋病(获得性免疫缺陷综合症, AIDS)，分为两型：HIV-1 型和 HIV-2 型，
是人类感染了艾滋病病毒 HIV(human immunodeficiency virus)所引起的传染性
疾病。自该疾病 1981 年被发现以来到 2007 年底,全世界死于艾滋病的人数已有 
2000 多万。据官方称，截止至 2009 年底，我国现存艾滋病病毒感染者和病人约






的药物。直到上个世纪 90 年代，Kuo-H Suing Lee 实验室在对植物天然产物进行
抗 HIV 活性筛选的时候，发现该化合物具有很好的抗 HIV 的活性，其
EC50=1.3μmol/L。该类化合物跟传统的抗 HIV 药物的结构具有很大的区别，因此


























DCK 具有很好的抗 HIV 的活性，而其对映异构体也有抗 HIV 的活性，但是
比 DCK 活性要差接近 10000 倍，因此认为该类化合物中 3’R,4’R 的绝对构型起
着至关重要的作用。DCK 的 EC50 值为 4×10-4μM，在相同的分析情况下，比齐多







HIV 活性。当使用 (R)-樟脑酰基时，化合物表现出较强的抗 HIV 活性，但较 DCK
稍差；当一个使用(S)-樟脑酰基，另一个使用体积较大的酰基(如金刚烷酰基)时， 
化合物表现出一定的抗 HIV 活性，但较 DCK 要差很多。这说明双(S)-樟脑酰基
对该类化合物保持抗 HIV 活性的重要性[15]。 
 因此，之后的结构改造，基本都保留了双(S)-樟脑酰基以及 3’R,4’R 的绝对
构型。转而对凯林内酯的母核进行结构修饰，并且发现了一些活性比 DCK 更好
的化合物。谢蓝课题组对凯林内酯母核的 3,4,5,6 位进行了结构修饰，并且得到
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